Kingsview Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
Kingsview Wealth Management's ARKG Position: Q1 2026 in Review
Kingsview Wealth Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2026, closing a stake of 206,252 shares — an estimated $5.98M sold.
Kingsview Wealth Management first reported a position in ARKG in Q1 2021 and held it in 4 quarters. The position peaked at $5.98M in Q4 2025. 219 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.
- Kingsview Wealth Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2026 after selling out during the quarter.
- Kingsview Wealth Management sold 206,252 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $5.98M.
- Kingsview Wealth Management first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 4 quarters.
- Kingsview Wealth Management's ARK Genomic Revolution ETF position peaked at $5.98M in Q4 2025.
- 219 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.
Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.